Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.68 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.68 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.66 |
| ▸ | MAOB | P27338 | 4/20 | 0.64 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.64 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.62 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15596323 | 0.90 | MAOB (0.66) | NR4A1NR4A2NR4A3LMNACYP1A2 | |
| SCHEMBL4602806 | 0.85 | MAOB (0.70) | NR4A1NR4A2NR4A3LMNACYP1A2 | |
| SCHEMBL5378418 | 0.85 | NR4A1 (0.64) | NR4A1NR4A2NR4A3LMNACYP1A2 | |
| SCHEMBL1069504 | 0.84 | MAOB (0.63) | NR4A1NR4A2NR4A3MAOBPARP10 | |
| SCHEMBL521489 | 0.84 | NR4A1 (0.72) | NR4A1NR4A2NR4A3LMNACYP1A2 | |
| SCHEMBL16795721 | 0.84 | NR4A1 (0.62) | NR4A1NR4A2NR4A3LMNACYP1A2 | |
| SCHEMBL339813 | 0.83 | LMNA (0.82) | NR4A1NR4A2NR4A3LMNACYP1A2 | |
| SCHEMBL1092594 | 0.82 | NR4A1 (0.70) | NR4A1NR4A2NR4A3LMNACYP1A2 | |
| SCHEMBL5383753 | 0.82 | NR4A1 (0.60) | NR4A1NR4A2NR4A3LMNACYP1A2 | |
| SCHEMBL19157998 | 0.82 | MAOB (0.61) | NR4A1NR4A2NR4A3LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142379-A1 | CYCLOHEXYL DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | JAIN NARESHKUMAR F | 2007-06-21 | — | — | US | disclosed |
| US-7183445-B2 | Cyclohexyl derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V (BE) | 2007-02-27 | — | — | US | disclosed |
| EP-1633692-A2 | CYCLOHEXYL DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-15 | — | — | EP | disclosed |
| US-20050009799-A1 | Cyclohexyl derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-13 | — | — | US | disclosed |
| WO-2005000775-A2 | CYCLOHEXYL DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009799-A1 | Cyclohexyl derivatives as selective estrogen receptor modulators | ESR2, GPER1, ESR1 | NR4A1 47/4885NR4A2 30/4885NR4A3 32/4885 |
| US-20070142379-A1 | CYCLOHEXYL DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | ESR2, GPER1, ESR1 | NR4A1 47/4885NR4A2 30/4885NR4A3 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.